- Russia started human trials of Sputnik Light in January, and the studies are still ongoing, according to official records.
- Russia’s Sputnik Light vaccine, which received regulatory approval on Thursday, will be priced at less than $10.
- The single-dose version of the country’s Sputnik V vaccine has demonstrated 79.4 percent efficacy in a real-world study as part of Russia’s mass vaccination campaign.
- The Russian authorities argued that the move could accelerate the process of achieving herd immunity against the coronavirus.
According to an article published in News 18, Russia’s Sputnik Light vaccine, which received regulatory approval on Thursday, will be priced at less than $10 and argued that the move could accelerate the process of achieving herd immunity against the coronavirus.
Vaccine Testing & Trials
Sputnik Light, identical to the first dose of the two-dose Sputnik V, has yet to complete the advanced testing needed to ensure its safety and effectiveness in line with established scientific protocols. The human trials of Sputnik Light were started in January, and the studies are underway, as per the official records.
Dosage Differences
A heterologous vaccine regimen, Sputnik V uses two different adenoviruses for the first and the second dose of vaccine. The prime or the first dose is rAd26 and the second or booster dose consists of rAd5. The new version, Sputnik Light is Sputnik V’s prime dose rAd26 and has been approved as a standalone vaccine.
Fight against Covid
Sputnik Light became the fourth COVID-19 vaccine, developed domestically, to get approval in Russia. Commenting on the decision to authorize it for use, President Vladimir Putin said Thursday, “It’s nice to know that this range of tools (against COVID-19) is expanding.”